Synchronous/Metachronous Prostate Cancer with Other Cancer Sites-The Experience of a Single Center in Romania.

Background and

Objectives

The management of patients with multiple primary malignancies (MPMs) is performed by a multidisciplinary team whose purpose is to individualize the treatment plan and to determine the strategies that will improve the patient's care. The most commonly encountered malignancies are prostate cancer, colorectal cancer, lung, and bladder cancer. Prostate cancer may be synchronous or metachronous with other cancer sites. The risk factors for MPMs are viral infections, genetic factors, environmental factors, and oncological treatments (chemotherapy and radiotherapy). Materials and

Methods

In this retrospective cohort study, we analyzed 26 patients with either synchronous or metachronous prostate cancer with another cancer site, registered at "Sf. Apostol Andrei" County Emergency Hospital in Galati, Romania, over a 15-year time interval (2010-2025).This paper presents the clinical and therapeutic characteristics and the staging of synchronous/metachronous cancer sites. The stage of the disease was analyzed along with the time interval between the first cancer site and the second or the third cancer site occurrence; the undergone treatment was a multimodal one.

Results

This paper discusses the analyzed cases and presents the articles published in the specialty literature regarding the stage of synchronous or metachronous prostate cancer with one or more cancer sites. The most common sites are presented, along with the importance of follow-up and a complex therapeutic management depending on the stage of primary tumors.

Conclusions

This series represents a cohort study regarding synchronous/metachronous prostate cancer with other cancer sites (26 cases over a 15-year time period). This case series adds more experience to the already existing experience in the literature, providing guidelines to clinicians in order to make the right decisions regarding the treatment of this disease.